Lilly expects greater-than-predicted drop in sales
Lilly's financial forecasts for 2014 have fallen short of the predictions that had been made by analysts, with the company expecting sales of between 19.2 billion and 19.8 billion US dollars against predictions that were, according to The Irish Times, above the higher amount.
The US pharma giant is weathering generic competition with a number of expiring patents.
"We are prepared for this challenge and are positioned to return to growth and expand margins in 2015 and beyond."
Derica Rice, chief financial officer, Lilly.
John Lechleiter, chief executive, president and chairman, Lilly.
Related news:
Eli Lilly issues profit warning (The Irish Times).
Reference links:
Lilly announces 2014 financial guidance, reconfirms 2013 expectations (Lilly statement for investors).